<h6>Objective :</h6><p>Licensing Partners Identification for client’s proprietary technology based neonatal MSCsOpportunity Assessment through Secondary &amp; Primary Intelligence.</p><h6>Problem Statement:</h6><p>A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.</p><h6>Our Methodology:</h6><ul><li>Stem Cell Market Assessment</li><li>Companies Assessment Portfolio Assessment</li><li>Deal/Investment Assessment</li><li>Interest in Client’s MSC</li><li>20 Potential Partners</li></ul><h6>Results:</h6><ul><li>Matrix Analysis positioned the top 20 companies researched.</li><li>The client could assess the Top companies which would effectively fit their strategic needs and objectives (the TARGET quadrant).</li><li>DelveInsight fixed meetings with these probably 4-5 companies for the client to take discussions forward.</li></ul>

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain. 

Out-Licensing Opportunity

Review case study how a Europe based client involved DelveInsight for licensing out his product to a partner.